Free tool
FAERS Monitor: Gemtesa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213006 or its brand name (Gemtesa, Vibegron). Reports on generic versions are filed under their own applications.
Reports
8,828
Serious
2,702
31% of reports
Hospitalization
1,007
Death reported
462
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,194
- diarrhoea440
- headache419
- urinary tract infection392
- urinary retention335
- death332
- fatigue308
- nausea288
- drug effect less than expected285
- inability to afford medication266
- constipation263
- dizziness243
- fall242
- urinary incontinence232
- therapy interrupted223
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 19 |
| 2021 | 211 |
| 2022 | 191 |
| 2023 | 1,842 |
| 2024 | 2,002 |
| 2025 | 2,278 |
| 2026 | 2,266 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,331 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inability to afford medicationSignal | 266 | 65.5 | 58.1 | 16,399 |
| drug effect less than expectedSignal | 285 | 46.7 | 41.6 | 12,465 |
| urinary retentionSignal | 335 | 24.2 | 21.7 | 7,350 |
| urinary incontinenceSignal | 232 | 18.8 | 16.5 | 3,866 |
| therapy interruptedSignal | 223 | 7.5 | 6.5 | 1,240 |
| urinary tract infectionSignal | 392 | 5.5 | 5.0 | 1,442 |
| constipationSignal | 263 | 2.9 | 2.6 | 323 |
| drug ineffectiveSignal | 1,194 | 2.2 | 2.0 | 791 |
| fall | 242 | 1.7 | 1.5 | 75 |
| diarrhoea | 440 | 1.6 | 1.5 | 108 |
| headache | 419 | 1.6 | 1.5 | 95 |
| dizziness | 243 | 1.2 | 1.0 | 5 |
| fatigue | 308 | 0.9 | 0.8 | 1 |
| death | 332 | 0.9 | 0.8 | 2 |
| nausea | 288 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.